language
Hundred Grams News
28
2025/04
On the afternoon of April 23, the Jiangsu Provincial Center for Disease Prevention and Control held a strategic cooperation symposium in Nanjing with Changchun Beacon Biotechnology Co., Ltd. (hereinafter referred to as “Beacon Biotech”).
21
2025/04
On April 15, 2025, the “Medical and Preventive Care Together: Saying Goodbye to the ‘Pain’ That We Breathe” — “Shingles Patients Speak” series of initiatives, together with the launch event for the report “Study on the Disease Burden and Economic Evaluation of Herpes Zoster in China,” was grandly held at the People’s Medical Publishing House Hotel in Beijing.
08
2025/04
Recently, a “Investigator-Initiated Clinical Trial 1” of the novel mRNA tumor vaccine TMT101, independently developed by Chuanxin Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as “Chuanxin Bio”), an equity-participated company of Changchun Beacon Biotechnology Co., Ltd. (hereinafter referred to as “Beacon Bio”), was successfully completed at Peking Union Medical College Hospital, with the first patient dosing and dose-limiting toxicity (DLT) observation conducted without any DLT events. The trial will now proceed as planned with the enrollment and dosing of subsequent patients.
31
2025/03
On March 25, 2025, Beacon Bio’s 2025 Annual Quality Management Conference was solemnly held at the Qinei Hall, with the participation of all employees at Level 4 and above.
22
2024/10
“Promoting High-Quality Development and Preventing Financial Risks”—“2024 World Investor Week” Event
To thoroughly implement the spirit of the Third Plenary Session of the 20th CPC Central Committee, the Central Financial Work Conference, and the new “Nine Measures for National Financial Development,” and to effectively guard against financial risks, we are now launching the “2024 World Investor Week” initiative, with the aim of continuously enhancing investors’ awareness of rational investing and risk management.